BioCryst Q3 Revenue $180.3M, Net Income $37.9M; Raises Total Revenue Guidance
BCRX sits 39% above its 52-week low of $6.23.
Summary
BioCryst reported Q3 revenue of $180.3 million and net income of $37.9 million, then raised full-year total revenue guidance to $715-$730 million and lowered its non-GAAP operating expense outlook.
Key Events · Earnings and Guidance · BCRX
-
Q3 Profit on $180.3M Revenue
Total revenue of $180.3 million (+13% year over year) produced GAAP operating profit of $53.3 million and net income of $37.9 million, or $0.14 per diluted share, versus $12.9 million a year earlier.
-
Total Revenue Guidance Raised
Full-year 2026 total revenue outlook lifted to $715-$730 million from $690-$715 million, driven by higher navenibart licensing revenue and RAPIVAB orders; ORLADEYO guidance held at $625-$645 million.
-
Operating Expense Outlook Cut
Non-GAAP operating expense guidance improved to $415-$425 million from $420-$440 million, reflecting progress on the Birmingham site closure, which is expected to cost about $10 million and save $30-$35 million annually.
-
Cash Position and Pipeline Timeline
Cash, cash equivalents, restricted cash and investments totaled $376.4 million at September 30, 2026 after positive quarterly cash flow; navenibart pivotal results are expected in Q3 2027 and BCX17725 initial patient data by end of 2026.
Analysis · BCRX · Life Sciences
BioCryst swung to a $37.9 million quarterly profit ($0.14 diluted per share) on $180.3 million of revenue, with ORLADEYO contributing $174.8 million. More important for the thesis, management raised full-year total revenue guidance to $715-$730 million from $690-$715 million and cut the non-GAAP operating expense outlook to $415-$425 million, while holding ORLADEYO guidance at $625-$645 million. The company also generated positive cash flow in the quarter and ended with $376.4 million in cash and investments, which funds the navenibart pivotal program through its Q3 2027 readout. The offset is that part of the revenue beat came from CareMed building initial specialty-pharmacy inventory, a timing item management expects to stay relatively stable rather than repeat as growth.
How filings like this one have moved
In the 30 days to Nov 4, 2026, 32.4% of the 2221 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BCRX was trading at $8.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $6.23 to $11.22. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.